Cargando…

Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study

Not all individuals treated for major depressive disorder (MDD) achieve recovery. This observational study examined the recovery rates in MDD patients and the patient characteristics associated with achieving recovery in a naturalistic clinical setting. Recovery was defined as having both clinical a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novick, Diego, Montgomery, William, Vorstenbosch, Ellen, Moneta, Maria Victoria, Dueñas, Héctor, Haro, Josep Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673035/ https://www.ncbi.nlm.nih.gov/pubmed/29184393 http://dx.doi.org/10.2147/PPA.S138750

Ejemplares similares

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
por: Novick, Diego, et al.
Publicado: (2015)

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick, Diego, et al.
Publicado: (2016)

Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East
por: Hong, Jihyung, et al.
Publicado: (2017)

Antidepressant medication treatment patterns in Asian patients with major depressive disorder
por: Novick, Diego, et al.
Publicado: (2015)

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
por: Hong, Jihyung, et al.
Publicado: (2015)

Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?
por: Novick, Diego, et al.
Publicado: (2013)

Should Unexplained Painful Physical Symptoms be Considered within the Spectrum of Depressive Symptoms?
por: Hong, Jihyung, et al.
Publicado: (2015)

Sex differences in the course of schizophrenia across diverse regions of the world
por: Novick, Diego, et al.
Publicado: (2016)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients
por: Novick, Diego, et al.
Publicado: (2016)

The neurocognitive profile of post‐traumatic stress disorder (PTSD), major depressive disorder (MDD), and PTSD with comorbid MDD
por: Koopowitz, Sheri‐Michelle, et al.
Publicado: (2021)

The possible role of the Microbiota-Gut-Brain-Axis in the etiology of Major depressive Disorder (MDD) The possible role of the Microbiota-Gut-Brain-Axis in the etiology of Major depressive Disorder (MDD) The possible role of the Microbiota-Gut-Brain-Axis in the etiology of Major depressive Disorder (MDD)
por: Pieters, T., et al.
Publicado: (2022)

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
por: Ng, Chong Guan, et al.
Publicado: (2023)

Comparison of Electroencephalography (EEG) Coherence between Major Depressive Disorder (MDD) without Comorbidity and MDD Comorbid with Internet Gaming Disorder
por: Youh, Joohyung, et al.
Publicado: (2017)

The process of major depressive disorder (MDD) in women referred to the health centers
por: Rahmati-Khameneh, Souraj, et al.
Publicado: (2011)

Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD)
por: Mosiołek, Anna, et al.
Publicado: (2021)

The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers
por: Proudman, David, et al.
Publicado: (2021)

Schizophrenia Outpatient Health Outcomes study: twelve-month findings
por: Novick, Diego, et al.
Publicado: (2012)

Skin conductance responses in Major Depressive Disorder (MDD) under mental arithmetic stress
por: Kim, Ah Young, et al.
Publicado: (2019)

S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review
por: Cuomo, Alessandro, et al.
Publicado: (2020)

Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Major depressive disorder (MDD) in adolescents with Borderline (BPD) and Shyzotypal personality disorder (STPD)
por: Kaleda, V., et al.
Publicado: (2023)

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study
por: Novick, Diego, et al.
Publicado: (2015)

Corrigendum: Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects
por: Alvarez-Mon, Miguel A., et al.
Publicado: (2021)

Major depressive disorder (MDD), antidepressants, and uncontrolled hypertension: A report of intraoperative autonomic dysregulation
por: Paraskeva, Anteia, et al.
Publicado: (2022)

Clinical evaluation of Major Depressive Disorder (MDD) and Borderline Personality Disorder(BPD) in youth adolescents
por: Kaleda, V., et al.
Publicado: (2022)

Exploring the Lived Experience on Recovery from Major Depressive Disorder (MDD) among Women Survivors and Five CHIME Concepts: A Qualitative Study
por: Idris, Afifah, et al.
Publicado: (2023)

ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharing
por: Schmaal, Lianne, et al.
Publicado: (2020)

Remote assessment of disease and relapse in major depressive disorder (RADAR-MDD): a multi-centre prospective cohort study protocol
por: Matcham, F., et al.
Publicado: (2019)

Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): recruitment, retention, and data availability in a longitudinal remote measurement study
por: Matcham, Faith, et al.
Publicado: (2022)

PHQ-8 Days: a measurement option for DSM-5 Major Depressive Disorder (MDD) severity
por: Dhingra, Satvinder S, et al.
Publicado: (2011)

MK4MDD: A Multi-Level Knowledge Base and Analysis Platform for Major Depressive Disorder
por: Guo, Liyuan, et al.
Publicado: (2012)

The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson’s Disease (PD) and Major Depressive Disorder (MDD)
por: Yang, Kai, et al.
Publicado: (2019)

Effects of Antidepressant Treatment on Neurotrophic Factors (BDNF and IGF-1) in Patients with Major Depressive Disorder (MDD)
por: Mosiołek, Anna, et al.
Publicado: (2021)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
por: Hong, Jihyung, et al.
Publicado: (2012)

Common variants in FKBP5 gene and major depressive disorder (MDD) susceptibility: a comprehensive meta-analysis
por: Rao, Shuquan, et al.
Publicado: (2016)

Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
por: Montano, C Brendan, et al.
Publicado: (2022)

Differential malondialdehyde (MDA) detection in plasma samples of patients with major depressive disorder (MDD): A potential biomarker
por: Alvarez-Mon, Miguel A, et al.
Publicado: (2022)

What factors explain the changes in major depressive disorder symptoms by age group during the COVID-19 pandemic? A longitudinal study
por: Gabarrell-Pascuet, Aina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0lr4bjmiloiu7mk4ohmjemiavi